|
|
|
|
409 * !
|
Thu, 8/12/2021,
2:00 PM -
3:50 PM
|
Virtual
|
|
Estimands in Oncology: Papers from an Industry Working Group — Topic-Contributed Papers
|
|
Biopharmaceutical Section, Lifetime Data Science Section, Biometrics Section, Caucus for Women in Statistics
|
|
Organizer(s): Jonathan Siegel, Bayer US
|
|
Chair(s): Jonathan Siegel, Bayer US
|
|
2:05 PM
|
Utilizing Surrogate Endpoints in Adaptive Designs with Delayed Treatment Effect
Jianchang Lin, Takeda Pharmaceuticals; Qing Li, Takeda Pharmaceuticals; Mengya Liu, Takeda Pharmaceuticals; Liwen Wu, University of Pittsburgh
|
|
2:25 PM
|
Use of Estimand Framework in Hematology Oncology Trials: Practical Implementation
Steven C Sun, Janssen; Satrajit Roychoudhury, Pfizer Inc.
|
|
2:45 PM
|
Logic-Respecting Efficacy Measures in the Presence of Prognostic or Predictive Biomarker Subgroups
Yi Liu, Nektar Therapeutic
|
|
3:05 PM
|
Treatment Switching and Estimands for Overall Survival in Oncology Clinical Trials: Issues and Controversies
Natalia Kan-Dobrosky, PPD Inc
|
|
3:25 PM
|
Discussant: Satrajit Roychoudhury, Pfizer Inc.
|
|
3:45 PM
|
Floor Discussion
|
